Company intelligence

ADARx Pharmaceuticals

Biotech
Last verified Sep 21, 2026

Key Metrics

Valuation
$1.74B
As of Sep 21, 2026Bloomberg
Total funding
$353M (pre-IPO)
As of Sep 21, 2026Bloomberg

Company Snapshot

ADARx Pharmaceuticals is a Biotech company. Latest valuation $1.74B (As of Sep 21, 2026, Bloomberg). Total funding $353M (pre-IPO) (As of Sep 21, 2026).

Recent changes

  1. Sep 21, 2026IPO $350M at $1.74B Bloomberg
  2. Sep 21, 2026First reported total funding: $353M (pre-IPO) Bloomberg
  3. Sep 21, 2026First reported valuation: $1.74B Bloomberg

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Sep 21, 2026ipo$350M$1.74B
OrbiMed AdvisorsVenrockBlackRock
Bloomberg

Investors

BlackRockOrbiMed AdvisorsVenrock

Latest Pulse

  1. ADARx Sets Terms For $350M IPO, AbbVie Buys InADARx Pharmaceuticals set terms for a $350 million Nasdaq IPO at $15-$17 a share targeting a $1.74 billion valuation, with AbbVie agreeing to buy a roughly 4.9% stake in a concurrent private placement.→

Coverage Timeline

newest first
  1. IPOADARx Sets Terms For $350M IPO, AbbVie Buys In→

All Coverage

IPO

ADARx Sets Terms For $350M IPO, AbbVie Buys In

Related Companies

Same sector
Attovia TherapeuticsApnimedBraveheart BioLatigo BiotherapeuticsScribe Therapeutics
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction